Pneumoconiosis future or investigational therapies
|
Pneumoconiosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pneumoconiosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Pneumoconiosis future or investigational therapies |
|
Pneumoconiosis future or investigational therapies in the news |
|
Risk calculators and risk factors for Pneumoconiosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Future therapies for pneumoconiosis are being considered.
Future or Investigational Therapies
Future therapies are being experimented on including inhibiting cytokines and the use of antioxidants. Investigational therapy also includes administration of bone marrow-derived mononuclear cells. [1] [2] [3] In the case of berylliosis, the use of 5-aminosalicylic acid (ASA) is being considered as it improved the beryllium lymphocyte proliferation test (BeLPT) test by 20% after use for six weeks. [4]
References
- ↑ Rimal B, Greenberg AK, Rom WN (2005). "Basic pathogenetic mechanisms in silicosis: current understanding". Curr Opin Pulm Med. 11 (2): 169–73. doi:10.1097/01.mcp.0000152998.11335.24. PMID 15699791.
- ↑ Maron-Gutierrez T, Castiglione RC, Xisto DG, Oliveira MG, Cruz FF, Peçanha R; et al. (2011). "Bone marrow-derived mononuclear cell therapy attenuates silica-induced lung fibrosis". Eur Respir J. 37 (5): 1217–25. doi:10.1183/09031936.00205009. PMID 20693250.
- ↑ Cavalli G, Fallanca F, Dinarello CA, Dagna L (2015). "Treating pulmonary silicosis by blocking interleukin 1". Am J Respir Crit Care Med. 191 (5): 596–8. doi:10.1164/rccm.201412-2150LE. PMID 25723826.
- ↑ Day BJ, Huang J, Barkes BQ, Gillespie M, Li L, Maier LA (2018). "5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects". Lung. 196 (1): 103–114. doi:10.1007/s00408-017-0062-x. PMID 29080069.